Talaris Therapeutics Stock Total Debt
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris Therapeutics fundamentals help investors to digest information that contributes to Talaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Talaris Stock. The fundamental analysis module provides a way to measure Talaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talaris Therapeutics stock.
Talaris |
Talaris Therapeutics Company Total Debt Analysis
Talaris Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Talaris Therapeutics Total Debt | 2.88 M |
Most of Talaris Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Talaris Therapeutics has a Total Debt of 2.88 M. This is 99.9% lower than that of the Biotechnology sector and 99.11% lower than that of the Health Care industry. The total debt for all United States stocks is 99.95% higher than that of the company.
Talaris Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talaris Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics of similar companies.Talaris Therapeutics is currently under evaluation in total debt category among its peers.
Talaris Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Shares Owned By Insiders | 11.90 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 340.1 K | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Net Income | (73.89 M) | |||
| Cash And Equivalents | 207.11 M | |||
| Cash Per Share | 4.97 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 28.92 X | |||
| Book Value Per Share | 3.49 X | |||
| Cash Flow From Operations | (60.86 M) | |||
| Short Ratio | 4.01 X | |||
| Earnings Per Share | (1.97) X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 84 | |||
| Beta | 2.18 | |||
| Market Capitalization | 125.73 M | |||
| Total Asset | 193.72 M | |||
| Retained Earnings | (164.74 M) | |||
| Working Capital | 174.15 M | |||
| Z Score | 24.78 | |||
| Net Asset | 193.72 M |
About Talaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Talaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |